BSEInsider Trading / SAST1 Sept 2026 · 1 Sept 2026, 10:43 am
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Prakruti R Pali
Asston Pharmaceuticals Ltd · 544445
✦ AI SummaryRelated Party
Asston Pharmaceuticals Ltd has received a disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Prakruti R Pali, which will be submitted to the BSE.
Analysis Scores
Earnings Impact1/10
Growth Catalyst1/10
Governance Concern2/10
Regulatory Risk2/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Asston Pharmaceuticals Ltd - 544445 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
Attachments (1)
📄pdf
Download →
00701E21_96DA_49DA_903D_CCE99DFA355E_104255.pdf
View document text
Date: 31st August, 2026
BSE Limited
Listing / Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai 400051
Sub: - Submission of disclosure under Regulation 29(1) of the SEBI (Substantial
Acquisition of Shares and Takeovers) Regulations, 2011
Pursuant to Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers)
Regulations, 2015, we hereby submit the disclosure received by the Company on 31st August,
2026, from Mrs. Prakruti R Pali.
Thanking You.
Yours Faithfully.
Kindly acknowledge receipt of the same.
Yours Truly,
For: Asston Pharmaceuticals Limited
Rishi Upadhaya
Company Secretary and Compliance Officer
A74324